Evidence map›Paper›PMID 39839777›Full record

ArticleFrontiers in oncology2024

Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study.

Luca F Valle, Fang-I Chu, Xiaoyan Wang, Andrew Erman, Jackie Hernandez, Elizabeth Kaoh, Nicolas Edgar, Ann C Raldow, Deborah J Wong, Michael L Steinberg and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Fang-I ChuDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Xiaoyan WangDepartment of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA, United States.
Andrew ErmanDepartment of Speech Pathology, University of California, Los Angeles, Los Angeles, CA, United States.
Jackie HernandezDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Elizabeth KaohDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Nicolas EdgarDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Ann C RaldowDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Deborah J WongDepartment of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
Robert K ChinDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
John V HegdeDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Preventing malnutrition during chemoradiation (CRT) for head and neck cancer is critical maximizing quality of life (QOL). We sought to assess patient-reported QOL outcomes after integrating exclusive liquid meal replacement with Soylent, a novel meal replacement agent, in patients with head and neck cancer undergoing CRT. Methods: Patients undergoing definitive or adjuvant concurrent CRT for locally advanced head and neck cancer enrolled on our single-institution, prospective phase II protocol evaluating nutritional replacement with Soylent. Patients who reached 5% body weight loss during CRT were transitioned to Soylent meal replacement for all nutritional needs. Patients who reached 10% body weight loss were recommended for gastrostomy tube (G-tube) placement. UW-QOL and FACT-H&N questionnaires assessed patient-reported QOL prior to the receipt of CRT and following conclusion of CRT. Paired t-test or Wilcoxon signed-rank test were performed to assess for differences between scores at each follow-up time point and baseline. Results: Of the 60 enrolled patients, 51/60 (85%) lost 5% of their pre-treatment body weight. Among these patients, 48/51 (94%) were successfully transitioned to Soylent. 22/48 patients subsequently lost 10% of their pre-treatment body weight, and 3/22 (14%) underwent G-tube placement with the remainder declining. This resulted in an overall G-tube rate of 5%. Among the 41 patients evaluable for QOL data, the nadirs for overall and health-related UW-QOL were reached at 1 month and rebounded to exceed baseline by 6 months. FACT-H&N survey scores were reduced from 32 at baseline to 20 at 1 month (adjusted p<0.001) and 26 at 3 months (adjusted p<0.001), but increased to 29, 30, and 27 at 6, 12, and 18 months, without significant differences as compared to baseline (adjusted p>0.38 for all). Conclusions: We report high patient adherence and a 5% G-tube placement rate with exclusive meal replacement with Soylent in patients undergoing concurrent CRT for head and neck cancers.

Indexed as

chemoradiationgastrostomy tubehead and neck cancernutritionquality of life

Identifiers

PMID39839777
PMCPMC11747389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.